Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Adds Directors to Board


SAN DIEGO--On August 28, following the successful close of its second round of funding, Structural Bioinformatics elected three new directors to its board. The appointees include Edgar Engleman, John Kenward, and Frank Kung.

Engleman is professor of medicine and pathology at the Stanford School of Medicine and is the cofounder of several companies. Kenward is a former executive of several pharmaceutical and biotechnology companies, including Ixsys, where he served as CEO, RepliGen, and Schering Plough. Kung has worked in the biotechnology industry for almost 20 years and has received numerous awards.

Structural Bioinformatics is the developer of a supercomputational operating system that makes possible the immediate use of gene sequence data in a broad range of structure-based drug discovery and design processes. The company is building corporate partnerships with pharmaceutical companies, gene discovery companies, and combinatorial chemistry companies.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.